EVR 6.7MSFT 0.21DAL -0.43JPM 1.28ATD.TO 0.245MTD 11.16CRWD -19.53
Eli Lilly & Co. (LLY)

NYSE:LLY

Eli Lilly & Co. (LLY)

1,125.27
+46.49 (4.31%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
217 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 5, 2026, 12:00 am

This summary was created by AI, based on 28 opinions in the last 12 months.

Eli Lilly & Co. (LLY) continues to thrive in the competitive landscape of GLP-1 weight-loss drugs, exhibiting strong growth potential and an active pipeline that includes a promising oral formulation. Experts praise LLY for its effective management and ability to gain market share, especially against competitors like Novo Nordisk (NVO). Despite recent market fluctuations and concerns over valuation, many analysts see LLY as a resilient leader in the pharmaceutical sector with a robust growth outlook, projected earnings growth around 20%. However, there are varied opinions on the current valuation, with some suggesting it has become overvalued amid high PE ratios. The company's recent partnership with technology firms like Nvidia and its expansions into treating other health issues enhance its potential for future profitability, bolstering its position as a compelling long-term investment in the healthcare landscape.

consensus icon
Consensus
Bullish
valuation icon
Valuation
Overvalued
review icon
Similar
NVO
BUY

Eli Lilly & Co.(LLY)

Dec 10, 2021
They hold an investor meeting on Wednesday. He expects good reports about several drugs: one for diabetes, another for Alzheimer's, which could be multi-billion franchises later.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$244.14

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Nov 22, 2021
A play on their Alzheimer's drug. He's long liked this.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$260.44

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Oct 08, 2021
The catalyst is the higher volumes from more people with diabetes. Diabetes is expected to rise by 20% by 2050. Lots of room to thrive. Novo Nordisk is first out of the gate and has an oral pill. LLY is not bad either.
Photo of David DriscollDavid DriscollUnlock Rating
$233.94

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Aug 18, 2021
Trades at 34x PE, because investors believe in LLY's new Alzheimer's drug. Also, all drug stocks are rallying because of the Delta variant and calls for a booster shot.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$268.52

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Eli Lilly & Co.(LLY)

Jun 07, 2021
Eli bounced today off Biogen's monster move after the FDA greenlit the latter's Alzheimer's drug.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$222.52

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Feb 22, 2021
A fave of his, up 19% YTD. Last month they delivered a terrific quarter and strong phase 2 data on their Alzheimer's drug, a possible game-changer. They also have a Covid antibody treatment that's already selling well. Most recentlty they delivered good phase 3 trial results on their cholesterol, weighr-loss drug for diabetes.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$200.68

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
RISKY

Eli Lilly & Co.(LLY)

Feb 16, 2021
Allan Tong’s Discover Picks LLY stock is now flirting with 52-week highs and trading above its 50- and 200-day moving averages. It trades at 25.55x and pays a 1.64% dividend. Essentially, positive news on March 12 will launch the LLY stock—and alleviate the suffering of many people and their families—but negative headlines will sink it, which might make it an even bigger bargain stock. Read 3 Bargain Stocks: Eli Lilly, Unilever & Apple for our full analysis.
Photo of Stockchase DiscoverStockchase Discover
Owned
Unlock Rating
$205.76

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Feb 11, 2021
Recent great results on phase 2 of Alzheimer's testing. There will be a lot of focus on the results around March 12. It it works, tremendous upside. Huge for families and for LLY. Diabetes franchise is performing extremely well. Oncology is building out.
Photo of Paul MacDonaldPaul MacDonaldUnlock Rating
$202.12

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Eli Lilly & Co.(LLY)

Jan 22, 2021
Their stock has rallied so much after vaccine hopes that it's now cooling off. Their pipeline of drugs is super. Any further positive news about their Alzheimer's drug push this stock higher.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$206.14

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Oct 19, 2020
He owns a basket. He owns this one for their oncology division. He has not owned it for anything COVID-related. Sometimes it is better to buy a basket of these companies.
Photo of Robert LauzonRobert Lauzon
Owned
Unlock Rating
$143.86

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Sep 21, 2020
They just released very promising data on their breast cancer drug (the previous update in June saw the stock pop), but the stock still dropped in price today. This is strange and undeserved, but the selling won't last.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$151.18

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Aug 02, 2019
He sold it several months ago, because it outperformed like crazy in late-2018. That was expected, because healthcare is the most defensive sector and Q4 was a bear market with fears of a recession. LLY made an acquisition in oncology and one of their big drugs got withdrawn. Novo Nordisk may launch a diabetes drug in September to fcompete with LLY.
Photo of David FingoldDavid Fingold
No
Unlock Rating
$111.60

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Jul 08, 2019
It has one of the best growth profiles on the street with EPS growth at 10%. It trades at a premium to its peers, though. They have some potential blockbuster drugs focused on diabetes and heart disease. Itt depends on the effectiveness of that drug. Now is a good entry point. (Analysts’ price target is $125.81)
Photo of Jamie Murray Jamie Murray
Owned
Unlock Rating
$111.52

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

May 30, 2019
The whole drug industry is a slow growth one. It is difficult to get top line growth. That growth tends to come from a revolving set of assets. MRK-N has a bit of a leg up and is growing rapidly. It has a long runway before patent expiration. He prefers MRK-N.
Photo of Gordon ReidGordon ReidUnlock Rating
$115.90

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
WATCH

Eli Lilly & Co.(LLY)

May 03, 2019
Likes it. One of better growth profiles for large cap pharma. Exceptional job building out the pipeline in oncology and diabetes. Cardiac drug seems like becoming the standard of care. Some hiccups, but the market gave them a pass. 14-15% EPS growth. 17x next year's earnings. Make sure the launches are on track next quarter.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$116.97

Stock price when the opinion was issued

$1148.00

As of Jun 05, 2026. Market Open.

biotechnologypharmaceutical
Showing 151 to 165 of 202 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO -0.77$270.17
BHP -2.07$88.78
TA.TO -2.08$18
V 2.68$322.86
TOU.TO -1.22$64.2

Today's Top Picks

EVR 6.7$346.79
MSFT 0.21$428.26
DAL -0.43$79.08
JPM 1.28$312.17
ATD.TO 0.245$81.035

Popular Articles

Latest Sell Signals

PRL.TO 0.15$21.35
CNQ.TO -0.42$65.8
SHOP.TO -0.66$160.88
RIO -2.46$105.4
BB.TO -0.95$13.45

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica